These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 27366711)

  • 41. Association of plasma neutrophil gelatinase-associated lipocalin with parameters of CKD-MBD in maintenance hemodialysis patients.
    Jia XY; Wei K; Chen J; Xi LH; Kong XL; Wei Y; Wang L; Wang ZS; Liu YP; Liang LM; Xu DM
    J Bone Miner Metab; 2021 Nov; 39(6):1058-1065. PubMed ID: 34392464
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chronic hemodialysis patients without marked elevation of intact parathyroid hormone are also good candidates for early intervention with cinacalcet.
    Nishida H; Masakane I; Kudo K; Ito M; Tanida H; Koshika M; Nishida W; Tomita Y
    Ther Apher Dial; 2013 Jun; 17(3):325-31. PubMed ID: 23735149
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients.
    Ramos AM; Albalate M; Vázquez S; Caramelo C; Egido J; Ortiz A
    Kidney Int Suppl; 2008 Dec; (111):S88-93. PubMed ID: 19034335
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD).
    O'Flaherty D; Sankaralingam A; Scully P; Manghat P; Goldsmith D; Hampson G
    Clin Biochem; 2013 Oct; 46(15):1405-9. PubMed ID: 23830844
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chronic Kidney Disease-Mineral Bone Disease Biomarkers in Kidney Transplant Patients.
    Hasparyk UG; Vigil FMB; Bartolomei VS; Nunes VM; Simões E Silva AC
    Curr Med Chem; 2022 Aug; 29(31):5230-5253. PubMed ID: 35306980
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease.
    Raji YR; Ajayi SO; Adeoye AM; Amodu O; Tayo BO; Salako BL
    Afr Health Sci; 2022 Mar; 22(1):344-351. PubMed ID: 36032486
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Changes in mineral and bone disorder management in a French cohort of hemodialysis patients between 2008 and 2012: The National Bone and Mineral Metabolism observatory (Photo-Graphe 2 and 3)].
    Pelletier S; Roth H; Bouchet JL; Drueke TB; Hannedouche T; Jean G; London G; Fouque D;
    Nephrol Ther; 2016 Jun; 12(3):171-7. PubMed ID: 26822333
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
    Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
    J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of kidney function, vitamin D deficiency, and circulating markers of mineral and bone disorders in CKD.
    Ureña-Torres P; Metzger M; Haymann JP; Karras A; Boffa JJ; Flamant M; Vrtovsnik F; Gauci C; Froissart M; Houillier P; Stengel B;
    Am J Kidney Dis; 2011 Oct; 58(4):544-53. PubMed ID: 21803465
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
    Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
    Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Are low plasma levels of 25-(OH)vitamin D a major risk factor for hyperparathyroidism independent of calcitriol in renal transplant patients?
    Lomonte C; Antonelli M; Vernaglione L; Cazzato F; Casucci F; Chimienti D; Bruno A; Cocola S; Verrelli EA; Basile C
    J Nephrol; 2005; 18(1):96-101. PubMed ID: 15772930
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reducing the risk of denosumab-induced hypocalcemia in patients with advanced chronic kidney disease: a quality improvement initiative.
    Kanagalingam T; Khan T; Sultan N; Cowan A; Thain J; Hoy C; Ledger S; Clemens KK
    Arch Osteoporos; 2023 Nov; 18(1):138. PubMed ID: 37985504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Regression analysis of serum bone metabolic markers and traditional Chinese medicine syndromes in patients with CKD-MBD].
    Yang HM; Meng XJ; Wu W; Liu YL; Zhai XJ
    Zhongguo Zhong Yao Za Zhi; 2017 Oct; 42(20):4027-4034. PubMed ID: 29243442
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rationale for Raising Current Clinical Practice Guideline Target for Serum 25-Hydroxyvitamin D in Chronic Kidney Disease.
    Strugnell SA; Sprague SM; Ashfaq A; Petkovich M; Bishop CW
    Am J Nephrol; 2019; 49(4):284-293. PubMed ID: 30878999
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of Vitamin D Metabolites with Parathyroid Hormone, Fibroblast Growth Factor-23, Calcium, and Phosphorus in Dogs with Various Stages of Chronic Kidney Disease.
    Parker VJ; Harjes LM; Dembek K; Young GS; Chew DJ; Toribio RE
    J Vet Intern Med; 2017 May; 31(3):791-798. PubMed ID: 28186657
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Diabetic Kidney Disease 3rd stage - laboratory markers of mineral bone disorder].
    Klimentová A; Ságová I; Prídavková D; Kantárová D; Makovický P; Sadloňová J; Mokáň M
    Vnitr Lek; 2016; 62(6):442-8. PubMed ID: 27485841
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients.
    Mehrotra R
    J Ren Nutr; 2006 Apr; 16(2):100-18. PubMed ID: 16567266
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effects and safety of high dose vitamin D3 in hemodialysis patients.
    Guella A; Abduelkarem AR; Hassanein MM
    Pharm Pract (Granada); 2023; 21(1):2773. PubMed ID: 37090466
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Diagnostic accuracy study comparing total alkaline phosphatase with intact parathyroid hormone 1-84 for the diagnosis of high turnover renal osteodystrophy in chronic renal failure on hemodialysis].
    Rojas González AM; Opazo Valenzuela M; Muñoz Navarro S
    Medwave; 2014 Sep; 14(8):e6014. PubMed ID: 25340338
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Association between Hemodialysis Patient Outcomes and Compliance with KDOQI and KDIGO Targets for Mineral and Bone Metabolism.
    Djukanović L; Dimković N; Marinković J; Djurić Ž; Knežević V; Lazarević T; Ljubenović S; Marković R; Rabrenović V
    Nephron; 2016; 132(3):168-74. PubMed ID: 26914677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.